Nevro Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
Piper Jaffray Remains Bullish on Nevro (NVRO) Following 2Q Beat and Raise
August 9, 2016 8:23 AM EDTPiper Jaffray reiterated an Overweight rating on Nevro Corp (NYSE: NVRO), and raised the price target to $112.00 (from $98.00), following the company's 2Q earnings report. 2Q16 revenues were $55.4 million, primarily due to the ongoing launch of HF10 therapy in the United States. Full-year 2016 revenue guidance was... More
Nevro (NVRO) Tops Q2 EPS by 16c; Guides FY16 Revenue Above Views
August 8, 2016 4:11 PM EDTNevro (NYSE: NVRO) reported Q2 EPS of ($0.31), $0.16 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $55.4 million versus the consensus estimate of $45.11 million.
GUIDANCE:
Nevro sees FY2016 revenue of $210-220 million, versus the consensus of $188.7... More



